Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Niraparib for Maintenance Treatment in Women of African Ancestry with Stage III-IV Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer after Front-line Treatment

Trial Status: active

This phase IV trial evaluates the genetic characteristics of African ancestry and environmental characteristics that may be related to the effects, both good and bad, of niraparib in women with stage III-IV ovarian cancer, fallopian tube cancer and primary peritoneal cancer following front-line treatment. Treatment usually includes surgery and chemotherapy and sometimes may also include treatment to keep the cancer from coming back (maintenance treatment). However, maintenance treatment may not work the same for everyone for many reasons, including race or ethnicity. Genes are made up of deoxyribonucleic acid (DNA) which acts as the instruction book for the cells in the body. Genes are inherited from parents and control how the body grows and changes as well as how the body reacts to certain things, such as medications. Niraparib blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep tumor cells from repairing their damaged DNA, causing them to die. Niraparib is a type of poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor. Giving niraparib may be safe, tolerable, and/or effective in treating women of African ancestry with stage III-IV ovarian cancer, fallopian tube cancer or primary peritoneal cancer following front-line treatment.